SARS-CoV-2-neutralising antibody BGB-DXP593 in mild-to-moderate COVID-19: a multicentre, randomised, double-blind, phase 2 trial
-
Published:2023-03
Issue:
Volume:57
Page:101832
-
ISSN:2589-5370
-
Container-title:eClinicalMedicine
-
language:en
-
Short-container-title:eClinicalMedicine
Author:
Vega Ramses,
Antila MarttiORCID,
Perez Carlos,
Mookadam Mohamed,
Xie Fangjie,
Zhang Wei,
Rizwan AhsanORCID,
Yao Zhen,
Rasko John E.J.